This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Acetyl-L-Carnitine In Severe Hepatic Encephalopathy

This study has been completed.
Information provided by:
University of Catania Identifier:
First received: October 18, 2010
Last updated: NA
Last verified: December 2000
History: No changes posted
To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.

Condition Intervention
Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale) Drug: Acetyl-l-Carnitine Drug: placebo

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by University of Catania:

Study Start Date: July 2002
Estimated Study Completion Date: December 2005
Arms Assigned Interventions
Experimental: Acetyl-L-carnitine Drug: Acetyl-l-Carnitine
2g per day
Placebo Comparator: placebo Drug: placebo
twice per day


Ages Eligible for Study:   40 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • patients with severe hepatic encephalopathy (grade 3 of the West Haven grading scale) with hepatic cirrhosis

Exclusion Criteria:

  • Patients with a history of recent alcohol abuse, patients using psychotropic drugs (e.g., antipsychotics, interferon, benzodiazepines, anti-epileptics, sedatives and antidepressants)
  • Other exclusion criteria were the following: major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syndrome or bacterial peritonitis; acute superimposed liver injury;patients with metabolic disorders such as diabetes mellitus, unbalanced heart failure and/or respiratory failure or end-stage renal disease; any additional precipitating factors such as high protein intake (additional high-protein meals), constipation; illiteracy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01223768

Cannizzaro Hospital
Catania, Italy, 95126
Sponsors and Collaborators
University of Catania
  More Information Identifier: NCT01223768     History of Changes
Other Study ID Numbers: 8-12-00 C
Study First Received: October 18, 2010
Last Updated: October 18, 2010

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Nootropic Agents processed this record on August 22, 2017